angiotensin ii has been researched along with pitavastatin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatta, T; Irie, H; Kameyama, H; Kusaba, T; Kuwahara, N; Matsubara, H; Narumiya, H; Sasaki, S; Takeda, K; Tamagaki, K | 1 |
| Arimoto, T; Konta, T; Koyama, Y; Kubota, I; Niizeki, T; Shishido, T; Takahashi, H; Takeishi, Y | 1 |
| Inoguchi, T; Kobayashi, K; Nakayama, M; Nawata, H; Sasaki, S; Sato, N; Sonoda, N; Tsubouchi, H; Yu, HY | 1 |
| Ayajiki, K; Kashiwagi, A; Masada, M; Nishio, Y; Okamura, T; Shinozaki, K; Yoshida, Y | 1 |
| Aihara, K; Akaike, M; Azuma, H; Ikeda, Y; Ise, T; Ishikawa, K; Iwase, T; Matsumoto, T; Sumitomo, Y; Yagi, S; Yoshida, S | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Aihara, K; Akaike, M; Ikeda, Y; Ishikawa, K; Iwase, T; Matsumoto, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Hu, W; Jiang, WB | 1 |
| Egashira, K; Katsuki, S; Koga, JI; Matoba, T; Nakano, K; Nakashiro, S; Tsutsui, H; Umezu, R | 1 |
2 trial(s) available for angiotensin ii and pitavastatin
| Article | Year |
|---|---|
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
8 other study(ies) available for angiotensin ii and pitavastatin
| Article | Year |
|---|---|
HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells.
Topics: Amides; Analysis of Variance; Angiotensin II; Atorvastatin; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation; Glucuronidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Klotho Proteins; Membrane Proteins; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger | 2004 |
Pitavastatin inhibits cardiac hypertrophy in a rat model of progressive renal injury.
Topics: Angiotensin II; Animals; Animals, Newborn; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Disease Progression; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Kidney; Male; Myocytes, Cardiac; Nephrectomy; Phosphorylation; Quinolines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vasoconstrictor Agents | 2005 |
Statin attenuates high glucose-induced and angiotensin II-induced MAP kinase activity through inhibition of NAD(P)H oxidase activity in cultured mesangial cells.
Topics: Angiotensin II; Cells, Cultured; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesangial Cells; Mitogen-Activated Protein Kinases; NADPH Oxidases; Naphthalenes; Onium Compounds; Oxidative Stress; Quinolines; Sensitivity and Specificity; Structure-Activity Relationship | 2005 |
Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production.
Topics: Angiotensin II; Animals; Aorta; Blotting, Western; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation; GTP Cyclohydrolase; Insulin Resistance; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Quinolines; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Superoxides | 2007 |
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Topics: Angiotensin II; Animals; Cardiotonic Agents; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Quinolines; Renal Insufficiency; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Ventricular Remodeling | 2008 |
Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.
Topics: Analysis of Variance; Angiotensin II; Animals; Antioxidants; Atrial Fibrillation; Blood Pressure; Blotting, Western; Cardiomegaly; Cyclic N-Oxides; Echocardiography; Fibrosis; Heart Atria; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Quinolines; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Smad2 Protein; Smad3 Protein; Spin Labels; Transforming Growth Factor beta1 | 2010 |
Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins.
Topics: Angiotensin II; Animals; Calcium; Cardiomyopathy, Dilated; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Myocardium; Natriuretic Peptide, Brain; Peptide Fragments; Protein Kinase C beta; Quinolines; Random Allocation; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2014 |
Nanoparticle-Mediated Delivery of Pitavastatin to Monocytes/Macrophages Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apoe
Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apolipoproteins E; Chemokine CCL2; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Monocytes; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Quinolines | 2022 |